Electronic health record derived-impact of COVID-19 on myasthenia gravis

As effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerge, it is important to have timely real-word data that guides immunization prioritization for our patients and especially possibly more vulnerable neuromuscular populations [1]. Recent data have shown that patients with chronic autoimmune neuromuscular disorders who are on immunosuppression were more likely to require hospitalization with Coronavirus Disease 2019 (COVID-19) [2]. Similarly, recent preliminary data published from the COVID-19 Associated Risks and Effects in Myasthenia Gravis (CARE-MG) registry, demonstrated a mortality of 24% and MG relapse rate of 40% among 91 patients [3].
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research